Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON phase III trial of savolitinib + osimertinib versus platinum doublet chemotherapy in EGFR-mutant, MET-positive advanced non-small cell lung cancer after progression on osimertinib
2021-006374-24Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of savolitinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Apr 2022; status: active.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-006374-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006374-24.